Zacks Investment Research Upgrades Recro Pharma (REPH) to “Strong-Buy”

Zacks Investment Research upgraded shares of Recro Pharma (NASDAQ:REPH) from a hold rating to a strong-buy rating in a research note published on Wednesday morning. The firm currently has $8.25 target price on the specialty pharmaceutical company’s stock.

According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “

REPH has been the topic of several other research reports. ValuEngine lowered Recro Pharma from a buy rating to a hold rating in a research note on Monday, September 17th. Janney Montgomery Scott set a $13.00 price objective on Recro Pharma and gave the company a buy rating in a research note on Monday, October 1st. Finally, Oppenheimer set a $18.00 price objective on Recro Pharma and gave the company a buy rating in a research note on Wednesday, September 5th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $12.88.

NASDAQ:REPH traded up $0.16 on Wednesday, hitting $7.35. The company’s stock had a trading volume of 115,626 shares, compared to its average volume of 150,519. The company has a quick ratio of 1.42, a current ratio of 1.59 and a debt-to-equity ratio of 2.22. The firm has a market capitalization of $151.04 million, a price-to-earnings ratio of -3.69 and a beta of -0.51. Recro Pharma has a one year low of $4.78 and a one year high of $13.05.

Recro Pharma (NASDAQ:REPH) last released its quarterly earnings data on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.03. The firm had revenue of $18.28 million for the quarter, compared to analyst estimates of $16.77 million. Recro Pharma had a negative return on equity of 194.05% and a negative net margin of 79.42%. Equities research analysts expect that Recro Pharma will post -2.51 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in REPH. BlackRock Inc. increased its stake in shares of Recro Pharma by 27.6% during the second quarter. BlackRock Inc. now owns 1,144,988 shares of the specialty pharmaceutical company’s stock worth $5,747,000 after purchasing an additional 247,559 shares during the period. Newtyn Management LLC bought a new position in shares of Recro Pharma during the second quarter worth approximately $4,456,000. Engine Capital Management LP increased its stake in shares of Recro Pharma by 472.3% during the second quarter. Engine Capital Management LP now owns 391,307 shares of the specialty pharmaceutical company’s stock worth $1,964,000 after purchasing an additional 322,937 shares during the period. Renaissance Technologies LLC increased its stake in shares of Recro Pharma by 5.2% during the second quarter. Renaissance Technologies LLC now owns 381,300 shares of the specialty pharmaceutical company’s stock worth $1,914,000 after purchasing an additional 18,700 shares during the period. Finally, Acadian Asset Management LLC increased its stake in shares of Recro Pharma by 29.5% during the third quarter. Acadian Asset Management LLC now owns 290,124 shares of the specialty pharmaceutical company’s stock worth $2,063,000 after purchasing an additional 66,062 shares during the period. Hedge funds and other institutional investors own 54.79% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Featured Story: What is the float in trading stocks?

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply